Compare NIU & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NIU | BNR |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | China | China |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.8M | 252.7M |
| IPO Year | 2018 | 2019 |
| Metric | NIU | BNR |
|---|---|---|
| Price | $3.06 | $21.20 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.50 | N/A |
| AVG Volume (30 Days) | ★ 342.1K | 32.6K |
| Earning Date | 05-18-2026 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.54 | $111.65 |
| Revenue Next Year | $17.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.71 | $2.18 |
| 52 Week High | $5.67 | $41.72 |
| Indicator | NIU | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 50.11 | 55.95 |
| Support Level | $2.99 | $19.72 |
| Resistance Level | $3.22 | $23.42 |
| Average True Range (ATR) | 0.12 | 1.43 |
| MACD | 0.05 | 0.91 |
| Stochastic Oscillator | 70.93 | 81.30 |
Niu Technologies designs, manufactures and sells high-performance electric motorcycles, scooters, bicycles, and kick-scooters. The company has a product portfolio consisting of electric motorcycle, mopeds and bicycle series, including the NQi, MQi, UQi, F series, and others, and micro-mobility series, including the kick-scooter series KQi and the e-bike series BQi. The company's principal operations and geographic markets are predominantly in the People's Republic of China. It also generates revenue from Europe and other regions.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.